Cutting-edge research on HIV prevention
Large HIV prevention clinical trials are vital to determining if new experimental products will work to prevent HIV, the results of which can be game-changers in advancing the field of HIV interventions.
FHI 360 serves as the leadership and operations center for the HIV Prevention Trials Network (HPTN), a global, collaborative, clinical trials network that develops and tests the safety and efficacy of HIV prevention interventions. In 2016, HPTN launched the first large-scale trial of cabotegravir, a long-acting injectable drug for pre-exposure prophylaxis (PrEP). If proven safe and effective, this drug would provide an alternative to daily oral tenofovir disoproxil fumarate/emtricitabine and would be the first long-acting drug for HIV prevention. More options could result in an increased uptake of PrEP and ultimately contribute to reaching global HIV prevention goals.
HPTN studies are regularly at the forefront of global HIV prevention research. In 2011, Science magazine recognized the HPTN 052 clinical trial as the Breakthrough of the Year for its finding that antiretroviral drugs reduce the risk of heterosexual transmission of HIV by 93 percent. By harnessing scientific excellence, HPTN research contributes to important milestones that bring us one step closer to ending the epidemic.
Photo credit (top): Seth Pincus, Elizabeth Fischer and Austin Athman/National Institute of Allergy and Infectious Diseases, National Institutes of Health | Photo credit (bottom): Mauro Vombe/FHI 360